p>(basic) 71,141,686 65,795,671 73,868,177 68,057,204
share (0.33) (0.37) (0.17) (0.10)
*) Excluding contributions from the Chemical Development Business.
**) Excluding contributions from Evotec Technologies.
Key figures of consolidated balance sheets according to IFRS
Evotec AG and Subsidiaries
Euro in thousands
30/09/07 31/12/06 Change in
Cash and cash
equivalents 60,432 78,723 (23.2)
capital (3,696) (10,606)*) (65.2)
portion of loans
and finance lease
obligations 7,111 11,906 (40.3)
equity 134,327 137,176 (2.1)
Total assets 168,395**) 205,526**) (18.1)
*) Excluding early payments received for Evotec Technologies.
**) Including assets held for sale.
SVP, Investor Relations & Corporate Communications
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved
. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia2
. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 2013
. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York4
. Evotec AG: R&D Update on 16 October 2007 Live on the Internet5
. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound6
. QMed, Inc. Reports July Medicare SNP Enrollments7
. Phlo Affiliate Reports Expanded Coverage to Oregon Border8
. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results9
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200710
. Carrington Reports Second Quarter 2007 Results11
. Avitar Reports Third Quarter Financial Results for Fiscal 2007